SCHEMBL3276910

SCHEMBL3276910

CC(C)(C)OC(=O)NCc1ccc(COc2cccc(Oc3ccnc(Cl)n3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.46
GAA P10253 1/20 0.41
NAMPT P43490 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PLAAT3 P53816 1/20 0.40
PLAAT5 Q96KN8 1/20 0.40
PLAAT2 Q9NWW9 1/20 0.40
PLAAT4 Q9UL19 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
SPHK2 Q9NRA0 1/20 0.39
SPHK1 Q9NYA1 1/20 0.39
MAP3K5 Q99683 1/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
RAB9A P51151 1/20 0.39
MAOA P21397 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3278773 0.89 HDAC1 (0.47) HDAC1GAANAMPTL3MBTL1PLAAT3
SCHEMBL3278527 0.87 HDAC1 (0.43) HDAC1NAMPTL3MBTL1MEN1KMT2A
SCHEMBL3279329 0.79 PLAAT3 (0.49) HDAC1GAANAMPTPLAAT3PLAAT5
SCHEMBL14447630 0.77 NTRK1 (0.44) NAMPTL3MBTL1
SCHEMBL25079168 0.77 MAOB (0.55) HDAC1GAAL3MBTL1NPC1RAB9A
SCHEMBL17136480 0.76 HDAC1 (0.65) HDAC1GAANAMPTL3MBTL1MEN1
SCHEMBL3278992 0.76 HDAC1 (0.44) HDAC1NAMPTL3MBTL1LOXLOXL2
SCHEMBL12921676 0.75 AAK1 (0.53) HDAC1GAANAMPTL3MBTL1
SCHEMBL2566299 0.74 HDAC1 (0.58) HDAC1MEN1KMT2ASPHK2SPHK1
SCHEMBL3278076 0.73 F2 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7700605-B2 2-cyano-pyrimidines and-triazines as cysteine protease inhibitors NOVARTIS AG (CH) 2010-04-20 US disclosed
US-20080214548-A1 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors FLOHR STEFANIE 2008-09-04 US disclosed
EP-1907368-A1 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS Novartis AG (CH) 2008-04-09 EP disclosed
WO-2007009715-A1 2-CYANO-PYRIMIDINES AND -TRIAZINES AS CYSTEINE PROTEASE INHIBITORS NOVARTIS AG (CH) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214548-A1 2-Cyano-Pyrimidines and-Triazines as Cysteine Protease Inhibitors USP2, UCHL3, UCHL5 HDAC1 1790/4885GAA 443/4885NAMPT 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.